Jounce Therapeutics
1030 Massachusetts Avenue
Cambridge
Massachusetts
02138
United States
Tel: 857-259-3840
Fax: 617-812-5345
Website: http://www.jouncetx.com/
About Jounce Therapeutics
Jounce Therapeutics is focused on the discovery and development of novel cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
This transformational approach has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life.
Jounce is building upon the unparalleled expertise of its renowned scientific founders – world leaders in the fields of immunology, cancer biology and clinical and translational medicine in cancer – and its increasing understanding of how cancer cells communicate and interact with the immune system to position the company at the forefront of cancer immunotherapy drug discovery and development.
Based in Cambridge, Mass., Jounce is a private company launched in 2013 with $47 million in Series A venture capital financing by Third Rock Ventures.
126 articles about Jounce Therapeutics
-
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
4/28/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that two trial in progress posters, on the Phase 1 INNATE clinical trial and the Phase 2 SELECT clinical trial, will be presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting being held June 4-8, 2021.
-
Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021
4/27/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2021 financial results and provide a corporate update before market open on Tuesday, May 4, 2021.
-
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
4/12/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer.
-
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
4/10/2021
Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature
-
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
3/12/2021
Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $11.25 per share,
-
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting
3/10/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that preclinical data informing indication selection for the clinical development of its lead macrophage program, JTX-8064, will be presented in a poster session at the upcoming 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
-
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock - Mar 10, 2021
3/10/2021
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it has priced an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $11.25 per share, which would result in gross proceeds of approximately $56.25 million, before underwriting discounts and commissions.
-
Jounce Therapeutics Announces Proposed Offering of Common Stock
3/9/2021
Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it is offering to sell shares of its common stock in an underwritten public offering.
-
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
2/25/2021
- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 - - Ended 2020 with $213.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET -
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in March 2021
2/23/2021
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that Jounce management will present at several upcoming investor conferences
-
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
2/18/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update before market open on Thursday, February 25, 2021.
-
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
2/12/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors.
-
As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.
-
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
1/13/2021
- INNATE is a robust Phase 1 study designed to dose escalate quickly and demonstrate proof of concept for JTX-8064 monotherapy and PD-1i combinations - - Tumor-specific expansion cohorts to include PD-(L)1i resistant and sensitive tumors and PD-(L)1i naïve and experienced patients -
-
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
1/8/2021
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor conferences:
-
Jounce Therapeutics Added to NASDAQ Biotechnology Index - Dec 16, 2020
12/16/2020
Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that it has been selected for addition to the NASDAQ Biotechnology Index, effective prior to market open on Monday, December 21, 2020.
-
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/25/2020
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president, and Elizabeth Trehu, M.D., chief medical officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
-
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
11/16/2020
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce’s PD-1 inhibitor, JTX-4014 - - O n track to begin enrollment by year-end 2020 -
-
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
11/11/2020
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported new preclinical data on JTX-8064, the first tumor-associated macrophage program from their Translational Science Platform, at the 2020 Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting.
-
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
11/9/2020
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Cowen 2020 IO Next Summit on Friday, November 13, 2020 at 12:15 p.m. ET.